A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Next Cure, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 57,700 shares of NXTC stock, worth $86,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57,700
Previous 57,700 -0.0%
Holding current value
$86,550
Previous $65,000 96.92%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$1.03 - $1.45 $515 - $725
-500 Reduced 0.86%
57,700 $65,000
Q3 2023

Nov 14, 2023

SELL
$1.29 - $1.84 $20,640 - $29,440
-16,000 Reduced 21.56%
58,200 $75,000
Q2 2023

Aug 14, 2023

SELL
$1.47 - $1.86 $47,922 - $60,636
-32,600 Reduced 30.52%
74,200 $133,000
Q1 2023

May 15, 2023

SELL
$1.46 - $1.83 $51,830 - $64,965
-35,500 Reduced 24.95%
106,800 $158,000
Q4 2022

Feb 14, 2023

SELL
$1.2 - $2.49 $13,080 - $27,141
-10,900 Reduced 7.11%
142,300 $200,000
Q3 2022

Nov 14, 2022

BUY
$2.97 - $5.19 $147,312 - $257,424
49,600 Added 47.88%
153,200 $421,000
Q2 2022

Aug 15, 2022

BUY
$3.38 - $5.27 $338 - $527
100 Added 0.1%
103,600 $487,000
Q1 2022

May 16, 2022

SELL
$4.76 - $6.24 $263,704 - $345,696
-55,400 Reduced 34.86%
103,500 $503,000
Q4 2021

Feb 14, 2022

SELL
$5.7 - $9.1 $228,570 - $364,910
-40,100 Reduced 20.15%
158,900 $953,000
Q3 2021

Nov 15, 2021

BUY
$6.74 - $8.02 $698,264 - $830,872
103,600 Added 108.6%
199,000 $1.34 Million
Q2 2021

Aug 16, 2021

SELL
$7.6 - $10.28 $139,840 - $189,152
-18,400 Reduced 16.17%
95,400 $766,000
Q1 2021

May 17, 2021

BUY
$9.81 - $13.88 $277,623 - $392,804
28,300 Added 33.1%
113,800 $1.14 Million
Q4 2020

Feb 16, 2021

SELL
$9.47 - $12.43 $831,466 - $1.09 Million
-87,800 Reduced 50.66%
85,500 $932,000
Q3 2020

Nov 16, 2020

BUY
$8.15 - $21.17 $1.16 Million - $3.02 Million
142,600 Added 464.5%
173,300 $1.53 Million
Q2 2020

Aug 14, 2020

BUY
$21.19 - $40.2 $650,533 - $1.23 Million
30,700 New
30,700 $658,000

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $41.6M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.